nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2D6—Lomustine—hematologic cancer	0.0294	0.056	CbGbCtD
Atomoxetine—CYP2D6—Idarubicin—hematologic cancer	0.0262	0.0499	CbGbCtD
Atomoxetine—CYP2C19—Bortezomib—hematologic cancer	0.0255	0.0485	CbGbCtD
Atomoxetine—CYP2D6—Hydroxyurea—hematologic cancer	0.0223	0.0424	CbGbCtD
Atomoxetine—CYP2C19—Thalidomide—hematologic cancer	0.0222	0.0423	CbGbCtD
Atomoxetine—CYP2C19—Teniposide—hematologic cancer	0.0212	0.0403	CbGbCtD
Atomoxetine—CYP3A4—Bexarotene—hematologic cancer	0.0201	0.0383	CbGbCtD
Atomoxetine—CYP2C19—Ifosfamide—hematologic cancer	0.0196	0.0372	CbGbCtD
Atomoxetine—CYP2D6—Bortezomib—hematologic cancer	0.0194	0.0369	CbGbCtD
Atomoxetine—CYP3A4—Lomustine—hematologic cancer	0.0187	0.0356	CbGbCtD
Atomoxetine—CYP3A4—Busulfan—hematologic cancer	0.0187	0.0356	CbGbCtD
Atomoxetine—CYP2C19—Imatinib—hematologic cancer	0.0187	0.0356	CbGbCtD
Atomoxetine—CYP3A4—Thiotepa—hematologic cancer	0.0167	0.0317	CbGbCtD
Atomoxetine—CYP2D6—Imatinib—hematologic cancer	0.0142	0.027	CbGbCtD
Atomoxetine—CYP3A4—Methoxsalen—hematologic cancer	0.013	0.0247	CbGbCtD
Atomoxetine—CYP2D6—Nilotinib—hematologic cancer	0.0129	0.0246	CbGbCtD
Atomoxetine—CYP2D6—Vinorelbine—hematologic cancer	0.0128	0.0244	CbGbCtD
Atomoxetine—CYP3A4—Bortezomib—hematologic cancer	0.0123	0.0235	CbGbCtD
Atomoxetine—CYP2C19—Prednisone—hematologic cancer	0.0123	0.0234	CbGbCtD
Atomoxetine—CYP3A4—Daunorubicin—hematologic cancer	0.0118	0.0224	CbGbCtD
Atomoxetine—CYP3A4—Cytarabine—hematologic cancer	0.0104	0.0198	CbGbCtD
Atomoxetine—CYP3A4—Teniposide—hematologic cancer	0.0102	0.0195	CbGbCtD
Atomoxetine—CYP3A4—Ifosfamide—hematologic cancer	0.00946	0.018	CbGbCtD
Atomoxetine—CYP3A4—Imatinib—hematologic cancer	0.00903	0.0172	CbGbCtD
Atomoxetine—CYP3A4—Ruxolitinib—hematologic cancer	0.00851	0.0162	CbGbCtD
Atomoxetine—CYP3A4—Nilotinib—hematologic cancer	0.00821	0.0156	CbGbCtD
Atomoxetine—CYP3A4—Vinorelbine—hematologic cancer	0.00814	0.0155	CbGbCtD
Atomoxetine—CYP2D6—Vinblastine—hematologic cancer	0.00789	0.015	CbGbCtD
Atomoxetine—CYP2C19—Dexamethasone—hematologic cancer	0.00768	0.0146	CbGbCtD
Atomoxetine—CYP3A4—Triamcinolone—hematologic cancer	0.00744	0.0142	CbGbCtD
Atomoxetine—CYP3A4—Dasatinib—hematologic cancer	0.00725	0.0138	CbGbCtD
Atomoxetine—CYP3A4—Mitoxantrone—hematologic cancer	0.00717	0.0136	CbGbCtD
Atomoxetine—CYP3A4—Betamethasone—hematologic cancer	0.00639	0.0122	CbGbCtD
Atomoxetine—CYP3A4—Prednisolone—hematologic cancer	0.0063	0.012	CbGbCtD
Atomoxetine—CYP3A4—Prednisone—hematologic cancer	0.00595	0.0113	CbGbCtD
Atomoxetine—CYP2D6—Dexamethasone—hematologic cancer	0.00584	0.0111	CbGbCtD
Atomoxetine—CYP3A4—Irinotecan—hematologic cancer	0.00564	0.0107	CbGbCtD
Atomoxetine—CYP3A4—Vinblastine—hematologic cancer	0.00502	0.00954	CbGbCtD
Atomoxetine—CYP3A4—Vincristine—hematologic cancer	0.00493	0.00938	CbGbCtD
Atomoxetine—CYP2D6—Doxorubicin—hematologic cancer	0.00485	0.00922	CbGbCtD
Atomoxetine—CYP3A4—Etoposide—hematologic cancer	0.00452	0.0086	CbGbCtD
Atomoxetine—CYP3A4—Dexamethasone—hematologic cancer	0.00372	0.00707	CbGbCtD
Atomoxetine—NPY1R—hematopoietic system—hematologic cancer	0.00363	0.118	CbGeAlD
Atomoxetine—CYP3A4—Doxorubicin—hematologic cancer	0.00308	0.00586	CbGbCtD
Atomoxetine—NPY1R—gonad—hematologic cancer	0.00276	0.0898	CbGeAlD
Atomoxetine—NPY1R—blood—hematologic cancer	0.0024	0.0783	CbGeAlD
Atomoxetine—NPY1R—lung—hematologic cancer	0.00211	0.0686	CbGeAlD
Atomoxetine—NPY1R—testis—hematologic cancer	0.00199	0.0647	CbGeAlD
Atomoxetine—SLC6A3—hematopoietic system—hematologic cancer	0.00153	0.0497	CbGeAlD
Atomoxetine—NPY1R—lymph node—hematologic cancer	0.00144	0.0469	CbGeAlD
Atomoxetine—SLC6A4—hematopoietic system—hematologic cancer	0.0014	0.0455	CbGeAlD
Atomoxetine—CYP2C19—hematopoietic system—hematologic cancer	0.00116	0.0377	CbGeAlD
Atomoxetine—SLC6A2—gonad—hematologic cancer	0.000937	0.0305	CbGeAlD
Atomoxetine—SLC6A4—blood—hematologic cancer	0.000927	0.0302	CbGeAlD
Atomoxetine—SLC6A3—lung—hematologic cancer	0.000887	0.0289	CbGeAlD
Atomoxetine—SLC6A3—testis—hematologic cancer	0.000837	0.0272	CbGeAlD
Atomoxetine—SLC6A4—lung—hematologic cancer	0.000813	0.0265	CbGeAlD
Atomoxetine—CYP2C19—blood—hematologic cancer	0.000768	0.025	CbGeAlD
Atomoxetine—HTR2A—hematopoietic system—hematologic cancer	0.00074	0.0241	CbGeAlD
Atomoxetine—SLC6A2—lung—hematologic cancer	0.000715	0.0233	CbGeAlD
Atomoxetine—CYP3A4—hematopoietic system—hematologic cancer	0.000685	0.0223	CbGeAlD
Atomoxetine—SLC6A2—testis—hematologic cancer	0.000675	0.022	CbGeAlD
Atomoxetine—CYP2D6—hematopoietic system—hematologic cancer	0.000674	0.022	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—hematologic cancer	0.000659	0.235	CrCbGaD
Atomoxetine—HTR2A—gonad—hematologic cancer	0.000563	0.0183	CbGeAlD
Atomoxetine—HTR2A—blood—hematologic cancer	0.00049	0.016	CbGeAlD
Atomoxetine—SLC6A2—lymph node—hematologic cancer	0.000489	0.0159	CbGeAlD
Atomoxetine—CYP3A4—blood—hematologic cancer	0.000454	0.0148	CbGeAlD
Atomoxetine—CYP2D6—blood—hematologic cancer	0.000447	0.0145	CbGeAlD
Atomoxetine—HTR2A—lung—hematologic cancer	0.00043	0.014	CbGeAlD
Atomoxetine—HTR2A—testis—hematologic cancer	0.000406	0.0132	CbGeAlD
Atomoxetine—CYP2D6—testis—hematologic cancer	0.00037	0.012	CbGeAlD
Atomoxetine—Pseudoephedrine—TNF—hematologic cancer	0.000223	0.0792	CrCbGaD
Atomoxetine—Phenoxybenzamine—SLC22A1—hematologic cancer	0.00022	0.0784	CrCbGaD
Atomoxetine—Diphenhydramine—SLC22A1—hematologic cancer	0.000185	0.0658	CrCbGaD
Atomoxetine—Reboxetine—ABCB1—hematologic cancer	0.000165	0.0588	CrCbGaD
Atomoxetine—Desipramine—SLC22A1—hematologic cancer	0.000164	0.0586	CrCbGaD
Atomoxetine—Protriptyline—ABCB1—hematologic cancer	0.000152	0.054	CrCbGaD
Atomoxetine—Fenoprofen—ALB—hematologic cancer	0.000129	0.046	CrCbGaD
Atomoxetine—Phenprocoumon—ALB—hematologic cancer	0.000111	0.0397	CrCbGaD
Atomoxetine—Fluoxetine—ALB—hematologic cancer	0.000108	0.0386	CrCbGaD
Atomoxetine—Fluoxetine—ABCB1—hematologic cancer	0.000103	0.0368	CrCbGaD
Atomoxetine—Warfarin—ALB—hematologic cancer	9.89e-05	0.0352	CrCbGaD
Atomoxetine—Maprotiline—ABCB1—hematologic cancer	9.67e-05	0.0344	CrCbGaD
Atomoxetine—Propafenone—ABCB1—hematologic cancer	9.22e-05	0.0328	CrCbGaD
Atomoxetine—Ketoprofen—ALB—hematologic cancer	7.63e-05	0.0272	CrCbGaD
Atomoxetine—Propranolol—ABCB1—hematologic cancer	6.31e-05	0.0225	CrCbGaD
Atomoxetine—Nortriptyline—ALB—hematologic cancer	6.09e-05	0.0217	CrCbGaD
Atomoxetine—Methadone—ABCB1—hematologic cancer	5.18e-05	0.0185	CrCbGaD
Atomoxetine—Desipramine—ABCB1—hematologic cancer	4.78e-05	0.017	CrCbGaD
Atomoxetine—Dyspepsia—Dexamethasone—hematologic cancer	4.68e-05	0.000141	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—hematologic cancer	4.66e-05	0.00014	CcSEcCtD
Atomoxetine—Urticaria—Triamcinolone—hematologic cancer	4.66e-05	0.00014	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—hematologic cancer	4.65e-05	0.00014	CcSEcCtD
Atomoxetine—Asthenia—Etoposide—hematologic cancer	4.64e-05	0.000139	CcSEcCtD
Atomoxetine—Body temperature increased—Triamcinolone—hematologic cancer	4.63e-05	0.000139	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—hematologic cancer	4.63e-05	0.000139	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—hematologic cancer	4.63e-05	0.000139	CcSEcCtD
Atomoxetine—Decreased appetite—Dexamethasone—hematologic cancer	4.62e-05	0.000139	CcSEcCtD
Atomoxetine—Decreased appetite—Betamethasone—hematologic cancer	4.62e-05	0.000139	CcSEcCtD
Atomoxetine—Nausea—Irinotecan—hematologic cancer	4.62e-05	0.000139	CcSEcCtD
Atomoxetine—Nausea—Mitoxantrone—hematologic cancer	4.62e-05	0.000139	CcSEcCtD
Atomoxetine—Infection—Prednisone—hematologic cancer	4.6e-05	0.000138	CcSEcCtD
Atomoxetine—Mediastinal disorder—Epirubicin—hematologic cancer	4.6e-05	0.000138	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.59e-05	0.000138	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.59e-05	0.000138	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—hematologic cancer	4.59e-05	0.000138	CcSEcCtD
Atomoxetine—Fatigue—Betamethasone—hematologic cancer	4.59e-05	0.000138	CcSEcCtD
Atomoxetine—Fatigue—Dexamethasone—hematologic cancer	4.59e-05	0.000138	CcSEcCtD
Atomoxetine—Chills—Epirubicin—hematologic cancer	4.58e-05	0.000137	CcSEcCtD
Atomoxetine—Pruritus—Etoposide—hematologic cancer	4.57e-05	0.000137	CcSEcCtD
Atomoxetine—Shock—Prednisone—hematologic cancer	4.56e-05	0.000137	CcSEcCtD
Atomoxetine—Pain—Dexamethasone—hematologic cancer	4.55e-05	0.000137	CcSEcCtD
Atomoxetine—Pain—Betamethasone—hematologic cancer	4.55e-05	0.000137	CcSEcCtD
Atomoxetine—Nervous system disorder—Prednisone—hematologic cancer	4.54e-05	0.000136	CcSEcCtD
Atomoxetine—Tachycardia—Prednisone—hematologic cancer	4.52e-05	0.000136	CcSEcCtD
Atomoxetine—Skin disorder—Prednisone—hematologic cancer	4.5e-05	0.000135	CcSEcCtD
Atomoxetine—Nausea—Gemcitabine—hematologic cancer	4.5e-05	0.000135	CcSEcCtD
Atomoxetine—Vomiting—Cisplatin—hematologic cancer	4.49e-05	0.000135	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisone—hematologic cancer	4.48e-05	0.000135	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—hematologic cancer	4.47e-05	0.000134	CcSEcCtD
Atomoxetine—Mental disorder—Epirubicin—hematologic cancer	4.47e-05	0.000134	CcSEcCtD
Atomoxetine—Rash—Cisplatin—hematologic cancer	4.45e-05	0.000134	CcSEcCtD
Atomoxetine—Dermatitis—Cisplatin—hematologic cancer	4.44e-05	0.000134	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—hematologic cancer	4.44e-05	0.000133	CcSEcCtD
Atomoxetine—Diarrhoea—Etoposide—hematologic cancer	4.42e-05	0.000133	CcSEcCtD
Atomoxetine—Anorexia—Prednisone—hematologic cancer	4.42e-05	0.000133	CcSEcCtD
Atomoxetine—Feeling abnormal—Betamethasone—hematologic cancer	4.38e-05	0.000132	CcSEcCtD
Atomoxetine—Feeling abnormal—Dexamethasone—hematologic cancer	4.38e-05	0.000132	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—hematologic cancer	4.38e-05	0.000132	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—hematologic cancer	4.38e-05	0.000132	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—hematologic cancer	4.37e-05	0.000131	CcSEcCtD
Atomoxetine—Tension—Epirubicin—hematologic cancer	4.36e-05	0.000131	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Betamethasone—hematologic cancer	4.35e-05	0.000131	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.35e-05	0.000131	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—hematologic cancer	4.35e-05	0.000131	CcSEcCtD
Atomoxetine—Nervousness—Epirubicin—hematologic cancer	4.31e-05	0.00013	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—hematologic cancer	4.29e-05	0.000129	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—hematologic cancer	4.28e-05	0.000129	CcSEcCtD
Atomoxetine—Dizziness—Etoposide—hematologic cancer	4.27e-05	0.000128	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—hematologic cancer	4.27e-05	0.000128	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—hematologic cancer	4.26e-05	0.000128	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—hematologic cancer	4.25e-05	0.000128	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—hematologic cancer	4.23e-05	0.000127	CcSEcCtD
Atomoxetine—Urticaria—Betamethasone—hematologic cancer	4.23e-05	0.000127	CcSEcCtD
Atomoxetine—Urticaria—Dexamethasone—hematologic cancer	4.23e-05	0.000127	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.22e-05	0.000127	CcSEcCtD
Atomoxetine—Dizziness—Prednisolone—hematologic cancer	4.22e-05	0.000127	CcSEcCtD
Atomoxetine—Asthenia—Triamcinolone—hematologic cancer	4.21e-05	0.000126	CcSEcCtD
Atomoxetine—Abdominal pain—Betamethasone—hematologic cancer	4.2e-05	0.000126	CcSEcCtD
Atomoxetine—Body temperature increased—Betamethasone—hematologic cancer	4.2e-05	0.000126	CcSEcCtD
Atomoxetine—Abdominal pain—Dexamethasone—hematologic cancer	4.2e-05	0.000126	CcSEcCtD
Atomoxetine—Body temperature increased—Dexamethasone—hematologic cancer	4.2e-05	0.000126	CcSEcCtD
Atomoxetine—Nausea—Cisplatin—hematologic cancer	4.19e-05	0.000126	CcSEcCtD
Atomoxetine—Insomnia—Prednisone—hematologic cancer	4.19e-05	0.000126	CcSEcCtD
Atomoxetine—Vision blurred—Epirubicin—hematologic cancer	4.18e-05	0.000126	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisone—hematologic cancer	4.16e-05	0.000125	CcSEcCtD
Atomoxetine—Pruritus—Triamcinolone—hematologic cancer	4.15e-05	0.000125	CcSEcCtD
Atomoxetine—Cough—Methotrexate—hematologic cancer	4.14e-05	0.000124	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—hematologic cancer	4.13e-05	0.000124	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—hematologic cancer	4.11e-05	0.000123	CcSEcCtD
Atomoxetine—Vomiting—Etoposide—hematologic cancer	4.11e-05	0.000123	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—hematologic cancer	4.11e-05	0.000123	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—hematologic cancer	4.08e-05	0.000123	CcSEcCtD
Atomoxetine—Dyspepsia—Prednisone—hematologic cancer	4.08e-05	0.000123	CcSEcCtD
Atomoxetine—Rash—Etoposide—hematologic cancer	4.08e-05	0.000122	CcSEcCtD
Atomoxetine—Dermatitis—Etoposide—hematologic cancer	4.07e-05	0.000122	CcSEcCtD
Atomoxetine—Headache—Etoposide—hematologic cancer	4.05e-05	0.000122	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—hematologic cancer	4.05e-05	0.000122	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—hematologic cancer	4.04e-05	0.000121	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—hematologic cancer	4.04e-05	0.000121	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—hematologic cancer	4.04e-05	0.000121	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—hematologic cancer	4.03e-05	0.000121	CcSEcCtD
Atomoxetine—Decreased appetite—Prednisone—hematologic cancer	4.03e-05	0.000121	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—hematologic cancer	4.02e-05	0.000121	CcSEcCtD
Atomoxetine—Rash—Prednisolone—hematologic cancer	4.02e-05	0.000121	CcSEcCtD
Atomoxetine—Dermatitis—Prednisolone—hematologic cancer	4.02e-05	0.000121	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.01e-05	0.00012	CcSEcCtD
Atomoxetine—Fatigue—Prednisone—hematologic cancer	3.99e-05	0.00012	CcSEcCtD
Atomoxetine—Headache—Prednisolone—hematologic cancer	3.99e-05	0.00012	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—hematologic cancer	3.99e-05	0.00012	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—hematologic cancer	3.99e-05	0.00012	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—hematologic cancer	3.98e-05	0.00012	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—hematologic cancer	3.97e-05	0.000119	CcSEcCtD
Atomoxetine—Constipation—Prednisone—hematologic cancer	3.96e-05	0.000119	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—hematologic cancer	3.95e-05	0.000119	CcSEcCtD
Atomoxetine—Palpitations—Epirubicin—hematologic cancer	3.92e-05	0.000118	CcSEcCtD
Atomoxetine—Loss of consciousness—Epirubicin—hematologic cancer	3.9e-05	0.000117	CcSEcCtD
Atomoxetine—Dizziness—Triamcinolone—hematologic cancer	3.88e-05	0.000116	CcSEcCtD
Atomoxetine—Cough—Epirubicin—hematologic cancer	3.87e-05	0.000116	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—hematologic cancer	3.87e-05	0.000116	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—hematologic cancer	3.85e-05	0.000116	CcSEcCtD
Atomoxetine—Infection—Methotrexate—hematologic cancer	3.85e-05	0.000116	CcSEcCtD
Atomoxetine—Nausea—Etoposide—hematologic cancer	3.84e-05	0.000115	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisone—hematologic cancer	3.82e-05	0.000115	CcSEcCtD
Atomoxetine—Asthenia—Betamethasone—hematologic cancer	3.82e-05	0.000115	CcSEcCtD
Atomoxetine—Asthenia—Dexamethasone—hematologic cancer	3.82e-05	0.000115	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—hematologic cancer	3.8e-05	0.000114	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Prednisone—hematologic cancer	3.79e-05	0.000114	CcSEcCtD
Atomoxetine—Nausea—Prednisolone—hematologic cancer	3.79e-05	0.000114	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—hematologic cancer	3.78e-05	0.000114	CcSEcCtD
Atomoxetine—Chest pain—Epirubicin—hematologic cancer	3.78e-05	0.000114	CcSEcCtD
Atomoxetine—Arthralgia—Epirubicin—hematologic cancer	3.78e-05	0.000114	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—hematologic cancer	3.77e-05	0.000113	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—hematologic cancer	3.77e-05	0.000113	CcSEcCtD
Atomoxetine—Pruritus—Dexamethasone—hematologic cancer	3.76e-05	0.000113	CcSEcCtD
Atomoxetine—Pruritus—Betamethasone—hematologic cancer	3.76e-05	0.000113	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—hematologic cancer	3.76e-05	0.000113	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.75e-05	0.000113	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—hematologic cancer	3.74e-05	0.000112	CcSEcCtD
Atomoxetine—Vomiting—Triamcinolone—hematologic cancer	3.73e-05	0.000112	CcSEcCtD
Atomoxetine—Rash—Triamcinolone—hematologic cancer	3.7e-05	0.000111	CcSEcCtD
Atomoxetine—Dry mouth—Epirubicin—hematologic cancer	3.7e-05	0.000111	CcSEcCtD
Atomoxetine—Dermatitis—Triamcinolone—hematologic cancer	3.69e-05	0.000111	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—hematologic cancer	3.69e-05	0.000111	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—hematologic cancer	3.69e-05	0.000111	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—hematologic cancer	3.68e-05	0.000111	CcSEcCtD
Atomoxetine—Urticaria—Prednisone—hematologic cancer	3.68e-05	0.000111	CcSEcCtD
Atomoxetine—Headache—Triamcinolone—hematologic cancer	3.67e-05	0.00011	CcSEcCtD
Atomoxetine—Body temperature increased—Prednisone—hematologic cancer	3.66e-05	0.00011	CcSEcCtD
Atomoxetine—Abdominal pain—Prednisone—hematologic cancer	3.66e-05	0.00011	CcSEcCtD
Atomoxetine—Diarrhoea—Betamethasone—hematologic cancer	3.64e-05	0.000109	CcSEcCtD
Atomoxetine—Diarrhoea—Dexamethasone—hematologic cancer	3.64e-05	0.000109	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—hematologic cancer	3.63e-05	0.000109	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—hematologic cancer	3.61e-05	0.000108	CcSEcCtD
Atomoxetine—Infection—Epirubicin—hematologic cancer	3.6e-05	0.000108	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—hematologic cancer	3.58e-05	0.000108	CcSEcCtD
Atomoxetine—Shock—Epirubicin—hematologic cancer	3.56e-05	0.000107	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—hematologic cancer	3.56e-05	0.000107	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—hematologic cancer	3.55e-05	0.000107	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—hematologic cancer	3.54e-05	0.000106	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.53e-05	0.000106	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—hematologic cancer	3.52e-05	0.000106	CcSEcCtD
Atomoxetine—Dizziness—Dexamethasone—hematologic cancer	3.52e-05	0.000106	CcSEcCtD
Atomoxetine—Dizziness—Betamethasone—hematologic cancer	3.52e-05	0.000106	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—hematologic cancer	3.5e-05	0.000105	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—hematologic cancer	3.5e-05	0.000105	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—hematologic cancer	3.5e-05	0.000105	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—hematologic cancer	3.5e-05	0.000105	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—hematologic cancer	3.5e-05	0.000105	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—hematologic cancer	3.48e-05	0.000105	CcSEcCtD
Atomoxetine—Nausea—Triamcinolone—hematologic cancer	3.48e-05	0.000105	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—hematologic cancer	3.48e-05	0.000104	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.47e-05	0.000104	CcSEcCtD
Atomoxetine—Anorexia—Epirubicin—hematologic cancer	3.45e-05	0.000104	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—hematologic cancer	3.44e-05	0.000103	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—hematologic cancer	3.42e-05	0.000103	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—hematologic cancer	3.41e-05	0.000102	CcSEcCtD
Atomoxetine—Vomiting—Dexamethasone—hematologic cancer	3.38e-05	0.000102	CcSEcCtD
Atomoxetine—Vomiting—Betamethasone—hematologic cancer	3.38e-05	0.000102	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—hematologic cancer	3.37e-05	0.000101	CcSEcCtD
Atomoxetine—Rash—Dexamethasone—hematologic cancer	3.35e-05	0.000101	CcSEcCtD
Atomoxetine—Rash—Betamethasone—hematologic cancer	3.35e-05	0.000101	CcSEcCtD
Atomoxetine—Dermatitis—Dexamethasone—hematologic cancer	3.35e-05	0.000101	CcSEcCtD
Atomoxetine—Dermatitis—Betamethasone—hematologic cancer	3.35e-05	0.000101	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.34e-05	0.0001	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—hematologic cancer	3.34e-05	0.0001	CcSEcCtD
Atomoxetine—Headache—Dexamethasone—hematologic cancer	3.33e-05	0.0001	CcSEcCtD
Atomoxetine—Headache—Betamethasone—hematologic cancer	3.33e-05	0.0001	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—hematologic cancer	3.33e-05	0.0001	CcSEcCtD
Atomoxetine—Asthenia—Prednisone—hematologic cancer	3.32e-05	9.99e-05	CcSEcCtD
Atomoxetine—Pain—Methotrexate—hematologic cancer	3.31e-05	9.95e-05	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.3e-05	9.92e-05	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—hematologic cancer	3.3e-05	9.91e-05	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—hematologic cancer	3.29e-05	9.88e-05	CcSEcCtD
Atomoxetine—Pruritus—Prednisone—hematologic cancer	3.28e-05	9.85e-05	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—hematologic cancer	3.28e-05	9.84e-05	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—hematologic cancer	3.27e-05	9.83e-05	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—hematologic cancer	3.26e-05	9.78e-05	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—hematologic cancer	3.25e-05	9.77e-05	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—hematologic cancer	3.24e-05	9.74e-05	CcSEcCtD
Atomoxetine—Somnolence—Epirubicin—hematologic cancer	3.22e-05	9.68e-05	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—hematologic cancer	3.2e-05	9.6e-05	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—hematologic cancer	3.19e-05	9.58e-05	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—hematologic cancer	3.19e-05	9.58e-05	CcSEcCtD
Atomoxetine—Diarrhoea—Prednisone—hematologic cancer	3.17e-05	9.52e-05	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—hematologic cancer	3.17e-05	9.51e-05	CcSEcCtD
Atomoxetine—Nausea—Betamethasone—hematologic cancer	3.16e-05	9.49e-05	CcSEcCtD
Atomoxetine—Nausea—Dexamethasone—hematologic cancer	3.16e-05	9.49e-05	CcSEcCtD
Atomoxetine—Decreased appetite—Epirubicin—hematologic cancer	3.15e-05	9.46e-05	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.13e-05	9.4e-05	CcSEcCtD
Atomoxetine—Fatigue—Epirubicin—hematologic cancer	3.12e-05	9.38e-05	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—hematologic cancer	3.1e-05	9.31e-05	CcSEcCtD
Atomoxetine—Pain—Epirubicin—hematologic cancer	3.1e-05	9.31e-05	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—hematologic cancer	3.08e-05	9.24e-05	CcSEcCtD
Atomoxetine—Dizziness—Prednisone—hematologic cancer	3.06e-05	9.2e-05	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—hematologic cancer	3.06e-05	9.19e-05	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—hematologic cancer	3.06e-05	9.19e-05	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.05e-05	9.18e-05	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—hematologic cancer	3.03e-05	9.11e-05	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—hematologic cancer	3.01e-05	9.04e-05	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—hematologic cancer	2.99e-05	8.97e-05	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—hematologic cancer	2.98e-05	8.95e-05	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—hematologic cancer	2.96e-05	8.9e-05	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—hematologic cancer	2.95e-05	8.87e-05	CcSEcCtD
Atomoxetine—Vomiting—Prednisone—hematologic cancer	2.95e-05	8.85e-05	CcSEcCtD
Atomoxetine—Rash—Prednisone—hematologic cancer	2.92e-05	8.77e-05	CcSEcCtD
Atomoxetine—Dermatitis—Prednisone—hematologic cancer	2.92e-05	8.77e-05	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—hematologic cancer	2.91e-05	8.75e-05	CcSEcCtD
Atomoxetine—Headache—Prednisone—hematologic cancer	2.9e-05	8.72e-05	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.89e-05	8.69e-05	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—hematologic cancer	2.89e-05	8.68e-05	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—hematologic cancer	2.88e-05	8.65e-05	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—hematologic cancer	2.87e-05	8.61e-05	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—hematologic cancer	2.87e-05	8.61e-05	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—hematologic cancer	2.86e-05	8.6e-05	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—hematologic cancer	2.86e-05	8.6e-05	CcSEcCtD
Atomoxetine—Asthenia—Methotrexate—hematologic cancer	2.78e-05	8.34e-05	CcSEcCtD
Atomoxetine—Feeling abnormal—Doxorubicin—hematologic cancer	2.76e-05	8.3e-05	CcSEcCtD
Atomoxetine—Nausea—Prednisone—hematologic cancer	2.75e-05	8.27e-05	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.74e-05	8.24e-05	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—hematologic cancer	2.74e-05	8.23e-05	CcSEcCtD
Atomoxetine—Urticaria—Doxorubicin—hematologic cancer	2.66e-05	8e-05	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—hematologic cancer	2.65e-05	7.96e-05	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—hematologic cancer	2.65e-05	7.96e-05	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—hematologic cancer	2.65e-05	7.96e-05	CcSEcCtD
Atomoxetine—Asthenia—Epirubicin—hematologic cancer	2.6e-05	7.81e-05	CcSEcCtD
Atomoxetine—Pruritus—Epirubicin—hematologic cancer	2.56e-05	7.7e-05	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—hematologic cancer	2.56e-05	7.69e-05	CcSEcCtD
Atomoxetine—Diarrhoea—Epirubicin—hematologic cancer	2.48e-05	7.45e-05	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—hematologic cancer	2.46e-05	7.4e-05	CcSEcCtD
Atomoxetine—Rash—Methotrexate—hematologic cancer	2.44e-05	7.33e-05	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—hematologic cancer	2.44e-05	7.33e-05	CcSEcCtD
Atomoxetine—Headache—Methotrexate—hematologic cancer	2.43e-05	7.29e-05	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—hematologic cancer	2.41e-05	7.23e-05	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—hematologic cancer	2.4e-05	7.2e-05	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—hematologic cancer	2.37e-05	7.13e-05	CcSEcCtD
Atomoxetine—Vomiting—Epirubicin—hematologic cancer	2.3e-05	6.92e-05	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—hematologic cancer	2.3e-05	6.91e-05	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—hematologic cancer	2.29e-05	6.89e-05	CcSEcCtD
Atomoxetine—Rash—Epirubicin—hematologic cancer	2.28e-05	6.86e-05	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—hematologic cancer	2.28e-05	6.86e-05	CcSEcCtD
Atomoxetine—Headache—Epirubicin—hematologic cancer	2.27e-05	6.82e-05	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—hematologic cancer	2.22e-05	6.66e-05	CcSEcCtD
Atomoxetine—Nausea—Epirubicin—hematologic cancer	2.15e-05	6.47e-05	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—hematologic cancer	2.13e-05	6.4e-05	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—hematologic cancer	2.11e-05	6.35e-05	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—hematologic cancer	2.11e-05	6.34e-05	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—hematologic cancer	2.1e-05	6.31e-05	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—hematologic cancer	1.99e-05	5.98e-05	CcSEcCtD
Atomoxetine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	5.77e-06	5.34e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MTOR—hematologic cancer	5.74e-06	5.31e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CB—hematologic cancer	5.74e-06	5.31e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDGFB—hematologic cancer	5.71e-06	5.28e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.7e-06	5.27e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.7e-06	5.27e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CD80—hematologic cancer	5.68e-06	5.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—hematologic cancer	5.67e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KIT—hematologic cancer	5.67e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—NRAS—hematologic cancer	5.67e-06	5.25e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.65e-06	5.23e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—hematologic cancer	5.64e-06	5.22e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—hematologic cancer	5.59e-06	5.18e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC2—hematologic cancer	5.58e-06	5.16e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTPN11—hematologic cancer	5.57e-06	5.16e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—hematologic cancer	5.57e-06	5.15e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.55e-06	5.14e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1B—hematologic cancer	5.54e-06	5.13e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1B—hematologic cancer	5.5e-06	5.09e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—hematologic cancer	5.48e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—hematologic cancer	5.48e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—hematologic cancer	5.44e-06	5.03e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK3—hematologic cancer	5.43e-06	5.03e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CASP3—hematologic cancer	5.43e-06	5.02e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—hematologic cancer	5.42e-06	5.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CREB1—hematologic cancer	5.4e-06	5e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—hematologic cancer	5.4e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CASP3—hematologic cancer	5.39e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.39e-06	4.98e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1B—hematologic cancer	5.38e-06	4.98e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—hematologic cancer	5.38e-06	4.98e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NUP98—hematologic cancer	5.38e-06	4.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGFR3—hematologic cancer	5.37e-06	4.97e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—hematologic cancer	5.35e-06	4.95e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—hematologic cancer	5.33e-06	4.93e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—hematologic cancer	5.33e-06	4.93e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK14—hematologic cancer	5.31e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—hematologic cancer	5.29e-06	4.89e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL2—hematologic cancer	5.28e-06	4.89e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CASP3—hematologic cancer	5.28e-06	4.88e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—JUN—hematologic cancer	5.27e-06	4.88e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—hematologic cancer	5.27e-06	4.88e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6R—hematologic cancer	5.27e-06	4.88e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—hematologic cancer	5.27e-06	4.88e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CREBBP—hematologic cancer	5.26e-06	4.87e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—hematologic cancer	5.25e-06	4.85e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—hematologic cancer	5.24e-06	4.85e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—JUN—hematologic cancer	5.23e-06	4.84e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.22e-06	4.83e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.22e-06	4.83e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ESR1—hematologic cancer	5.21e-06	4.82e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NUP214—hematologic cancer	5.18e-06	4.79e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FN1—hematologic cancer	5.15e-06	4.76e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—hematologic cancer	5.14e-06	4.75e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JUN—hematologic cancer	5.13e-06	4.74e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—hematologic cancer	5.12e-06	4.74e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NCOR1—hematologic cancer	5.12e-06	4.73e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—hematologic cancer	5.12e-06	4.73e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1A—hematologic cancer	5.11e-06	4.73e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—hematologic cancer	5.1e-06	4.72e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NFKBIA—hematologic cancer	5.09e-06	4.71e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BAD—hematologic cancer	5.09e-06	4.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTR—hematologic cancer	5.08e-06	4.7e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.08e-06	4.7e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1A—hematologic cancer	5.07e-06	4.7e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—hematologic cancer	5.06e-06	4.68e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH1—hematologic cancer	5.04e-06	4.66e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAP2K1—hematologic cancer	5.02e-06	4.65e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK8—hematologic cancer	4.99e-06	4.62e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CD—hematologic cancer	4.99e-06	4.62e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO2—hematologic cancer	4.98e-06	4.61e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—hematologic cancer	4.98e-06	4.61e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	4.97e-06	4.6e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—hematologic cancer	4.96e-06	4.59e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK8—hematologic cancer	4.95e-06	4.58e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—hematologic cancer	4.94e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—hematologic cancer	4.94e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CD80—hematologic cancer	4.94e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—hematologic cancer	4.93e-06	4.56e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KIT—hematologic cancer	4.93e-06	4.56e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—NRAS—hematologic cancer	4.93e-06	4.56e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—hematologic cancer	4.88e-06	4.52e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EP300—hematologic cancer	4.87e-06	4.5e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	4.85e-06	4.49e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.85e-06	4.48e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTPN11—hematologic cancer	4.84e-06	4.48e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	4.84e-06	4.47e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.83e-06	4.47e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EP300—hematologic cancer	4.83e-06	4.47e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGF2—hematologic cancer	4.78e-06	4.42e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SRC—hematologic cancer	4.73e-06	4.38e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EP300—hematologic cancer	4.73e-06	4.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SDC1—hematologic cancer	4.72e-06	4.37e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	4.72e-06	4.37e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3R1—hematologic cancer	4.71e-06	4.36e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.7e-06	4.35e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.7e-06	4.35e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SRC—hematologic cancer	4.7e-06	4.34e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CREB1—hematologic cancer	4.69e-06	4.34e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—hematologic cancer	4.63e-06	4.29e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—hematologic cancer	4.61e-06	4.26e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SRC—hematologic cancer	4.6e-06	4.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL2—hematologic cancer	4.59e-06	4.25e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JAK2—hematologic cancer	4.58e-06	4.24e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6R—hematologic cancer	4.58e-06	4.23e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—hematologic cancer	4.57e-06	4.23e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	4.57e-06	4.23e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—hematologic cancer	4.56e-06	4.22e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRAS—hematologic cancer	4.55e-06	4.21e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—hematologic cancer	4.53e-06	4.19e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—hematologic cancer	4.52e-06	4.18e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRAS—hematologic cancer	4.52e-06	4.18e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	4.49e-06	4.15e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	4.48e-06	4.14e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MDM2—hematologic cancer	4.47e-06	4.13e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—hematologic cancer	4.43e-06	4.1e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRAS—hematologic cancer	4.42e-06	4.09e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	4.36e-06	4.03e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK3—hematologic cancer	4.36e-06	4.03e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MTOR—hematologic cancer	4.35e-06	4.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	4.35e-06	4.02e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	4.33e-06	4.01e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK3—hematologic cancer	4.33e-06	4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	4.29e-06	3.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	4.24e-06	3.92e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—hematologic cancer	4.24e-06	3.92e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	4.24e-06	3.92e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—hematologic cancer	4.23e-06	3.91e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—hematologic cancer	4.21e-06	3.89e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—hematologic cancer	4.2e-06	3.88e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.16e-06	3.85e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	4.15e-06	3.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGF2—hematologic cancer	4.15e-06	3.84e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—hematologic cancer	4.12e-06	3.81e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	4.11e-06	3.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	4.09e-06	3.78e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	4.08e-06	3.78e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	4.04e-06	3.73e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CD44—hematologic cancer	4.01e-06	3.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NQO1—hematologic cancer	4.01e-06	3.71e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CASP3—hematologic cancer	4e-06	3.7e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—hematologic cancer	3.99e-06	3.69e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.98e-06	3.69e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JAK2—hematologic cancer	3.98e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—hematologic cancer	3.97e-06	3.68e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—hematologic cancer	3.92e-06	3.62e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	3.9e-06	3.61e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—hematologic cancer	3.89e-06	3.6e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—hematologic cancer	3.89e-06	3.6e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUN—hematologic cancer	3.88e-06	3.59e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MDM2—hematologic cancer	3.88e-06	3.59e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—hematologic cancer	3.81e-06	3.52e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.8e-06	3.51e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYCS—hematologic cancer	3.8e-06	3.51e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	3.78e-06	3.49e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	3.78e-06	3.49e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.77e-06	3.49e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	3.77e-06	3.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—hematologic cancer	3.76e-06	3.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	3.68e-06	3.4e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	3.67e-06	3.39e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	3.6e-06	3.34e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—hematologic cancer	3.6e-06	3.33e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EP300—hematologic cancer	3.58e-06	3.32e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	3.57e-06	3.3e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	3.54e-06	3.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.52e-06	3.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	3.5e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	3.5e-06	3.24e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.49e-06	3.23e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SRC—hematologic cancer	3.48e-06	3.22e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—hematologic cancer	3.48e-06	3.22e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	3.47e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—hematologic cancer	3.47e-06	3.21e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—hematologic cancer	3.46e-06	3.2e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	3.45e-06	3.19e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	3.39e-06	3.14e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—hematologic cancer	3.38e-06	3.13e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	3.38e-06	3.13e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUN—hematologic cancer	3.37e-06	3.12e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	3.36e-06	3.11e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	3.35e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.35e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.34e-06	3.09e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—hematologic cancer	3.33e-06	3.08e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—hematologic cancer	3.3e-06	3.06e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—hematologic cancer	3.3e-06	3.05e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	3.27e-06	3.03e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	3.26e-06	3.02e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.24e-06	3e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—hematologic cancer	3.24e-06	2.99e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	3.21e-06	2.97e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	3.19e-06	2.95e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—hematologic cancer	3.19e-06	2.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	3.18e-06	2.95e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.17e-06	2.93e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—hematologic cancer	3.16e-06	2.93e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	3.15e-06	2.92e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—hematologic cancer	3.12e-06	2.89e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	3.11e-06	2.88e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EP300—hematologic cancer	3.11e-06	2.88e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—hematologic cancer	3.1e-06	2.87e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.08e-06	2.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.08e-06	2.85e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.07e-06	2.84e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—hematologic cancer	3.03e-06	2.81e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SRC—hematologic cancer	3.03e-06	2.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	2.95e-06	2.73e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—hematologic cancer	2.94e-06	2.72e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	2.92e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—hematologic cancer	2.92e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	2.91e-06	2.69e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.91e-06	2.69e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.9e-06	2.68e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.88e-06	2.67e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—hematologic cancer	2.86e-06	2.64e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	2.79e-06	2.58e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.72e-06	2.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.71e-06	2.51e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.7e-06	2.5e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.68e-06	2.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.65e-06	2.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.56e-06	2.37e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—hematologic cancer	2.51e-06	2.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2.51e-06	2.32e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.45e-06	2.27e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—EP300—hematologic cancer	2.4e-06	2.22e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—hematologic cancer	2.35e-06	2.17e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—hematologic cancer	2.31e-06	2.14e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	2.3e-06	2.13e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.28e-06	2.11e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—hematologic cancer	2.23e-06	2.06e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—EP300—hematologic cancer	2.21e-06	2.04e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	2.17e-06	2e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	2.13e-06	1.97e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.12e-06	1.96e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—hematologic cancer	2.04e-06	1.89e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.01e-06	1.86e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—hematologic cancer	1.98e-06	1.83e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.9e-06	1.75e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.88e-06	1.74e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.77e-06	1.64e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.75e-06	1.62e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.63e-06	1.51e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—hematologic cancer	1.51e-06	1.4e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—hematologic cancer	1.45e-06	1.34e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—EP300—hematologic cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—hematologic cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.07e-06	9.87e-06	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—hematologic cancer	8.72e-07	8.06e-06	CbGpPWpGaD
